The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dextromethorphan phenotyping as a test for prediction of tamoxifen (TAM) activation in breast cancer patients receiving adjuvant hormone therapy.
Milena Gusella
No relevant relationships to disclose
Laura Bertolaso
No relevant relationships to disclose
Felice Pasini
No relevant relationships to disclose
Yasmina Modena
No relevant relationships to disclose
Antonio Bononi
No relevant relationships to disclose
Anna Paola Fraccon
No relevant relationships to disclose
Donatella Da Corte
No relevant relationships to disclose
Elisabetta Cretella
No relevant relationships to disclose
Caterina Modonesi
No relevant relationships to disclose
Francesca Vastola
No relevant relationships to disclose
Linda Nicolardi
No relevant relationships to disclose
Cristina Pegoraro
No relevant relationships to disclose
Giovanni Rosti
No relevant relationships to disclose
Antonella Brunello
No relevant relationships to disclose
Romana Segati
No relevant relationships to disclose
Emilia Durante
No relevant relationships to disclose
Cristina Falci
No relevant relationships to disclose
Concetta Raiti
No relevant relationships to disclose
Elvira Rampello
No relevant relationships to disclose
Robeto Padrini
No relevant relationships to disclose